354 related articles for article (PubMed ID: 15091050)
1. Benign prostatic hyperplasia progression and its impact on treatment.
Djavan B; Waldert M; Ghawidel C; Marberger M
Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
[TBL] [Abstract][Full Text] [Related]
2. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
3. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
5. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
8. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
9. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ; Howe RW
BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
[TBL] [Abstract][Full Text] [Related]
10. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
11. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
12. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
13. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
O'Leary MP
Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
Kuritzky L
Compr Ther; 2005; 31(3):194-208. PubMed ID: 16110128
[TBL] [Abstract][Full Text] [Related]
15. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Lin VC; Liao CH; Wang CC; Kuo HC
J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
[TBL] [Abstract][Full Text] [Related]
16. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
17. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS.
Desgrandchamps F
Curr Opin Urol; 2004 Jan; 14(1):17-20. PubMed ID: 15091044
[TBL] [Abstract][Full Text] [Related]
18. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
19. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
20. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
